Transaction · 0001636282-26-000109

Burrows Scott L

Burrows Scott L, CFO, reported an open-market or private sale at Spyre Therapeutics, Inc. involving 4384.000000 shares for an estimated $381890.24. Reported holdings after the transaction were 100210.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SCFO
SYRESpyre Therapeutics, Inc.
Trade date
Sep 01, 2026
Filing date
Sep 04, 2026
View on SEC Insider profile
Estimated value-$381kShares × reported price
Shares traded4.38k$87.11 per share
Holdings after100kDirect
% of reported position traded4.19%This security and ownership context
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 104,594 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

SYRE price since this filing

Daily closing prices, with the filing date and available return windows
SYRE · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +10.5%1w ago +22.2%1d ago +0.4%
Returns since7d +1.8%30d +4.7%90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001636282-26-000109
Common Stock
Transaction date
Sep 01, 2026
Filed Sep 04, 2026, 01:33 AM · 3d delay
Shares
4,384 sh
$87.11 per share
Estimated value
-$381k
Computed from shares × price
Holdings after
100,210 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Cluster Selling Direct Ownership Repeat Seller 10b5-1 Detected
Filing-only score

-4 points

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • tenb5_1_detected-10 points

    is_10b5_1 = true

    Stored filing content includes detected 10b5-1 language.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Financial Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.

  2. F2

    The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.60 to $86.53, inclusive. The Reporting Person undertakes to provide to

  3. the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate p…

  4. (4 footnotes)

    within the range.

  5. F3

    The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.60 to $87.57, inclusive. The Reporting Person undertakes to provide to

  6. (3 footnotes)

    the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price

  7. F4

    The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.64 to $88.59, inclusive. The Reporting Person undertakes to provide to

  8. F5

    The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.69 to $89.38, inclusive. The Reporting Person undertakes to provide to

  9. F6

    The transaction reported reflects the sale of shares of the Issuer's common stock in satisfaction of the Reporting Person's tax liability in connection with the settlement of 33,738 restricted stock u…

  10. F7

    Includes 33,738 RSUs. Each RSU represents a contingent right to receive, upon vesting, one share of the Issuer's common stock. The RSUs vest on September 1, 2027, subject to the Reporting Person's con…

  11. F8

    This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter…

  12. of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's

  13. continued employment with the Issuer.

Original filing · 0001636282-26-000109
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

SYRE